Transcode Therapeutics Inc (RNAZ)

$10.97 +0.47 (4.48%)
Market Cap 9.15M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 16,200
Avg Vol 111,508
Day's Range N/A - N/A
Shares Out 834,000.00
Stochastic %K 100%
Beta 1.46
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857-837-3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
Scrubinski
Scrubinski Sep. 8 at 2:06 PM
$RNAZ is it early September yet?
0 · Reply
mbr60
mbr60 Sep. 8 at 1:49 PM
$RNAZ i think tomorrow 🔥🔥🔥
1 · Reply
Hovius
Hovius Sep. 8 at 1:03 PM
$RNAZ this all sounds beautiful, except for one thing…
0 · Reply
RNAZ089
RNAZ089 Sep. 8 at 12:38 PM
$RNAZ $OCTO wtf.................1000%....wow
0 · Reply
RNAZ089
RNAZ089 Sep. 7 at 10:58 PM
$RNAZ So here's my take: They did the reverse split in May, then the big players stepped in and started scooping up shares. After the July 23 cohort approval, we saw another round of heavy accumulation. If real news drops, I think the move will make July 23 look tiny. Only 800k shares out there + super low market cap = this thing has TEN-BAGGER written all over it. ■■This trial is the company's very first clinical - apart from the preclinical stage■■ 🚀 🚀 🚀
1 · Reply
drstock07
drstock07 Sep. 7 at 6:55 PM
$RNAZ The company completed Phase 1 with 16 patients, and some are still ongoing in the study. All prior updates confirmed no dose-limiting toxicities (No DLTs), which is a major strength at this stage. In the latest shareholders’ meeting, management clearly stated they expect to announce specific results in early September. Companies usually don’t commit to a timeframe unless they have clear and encouraging data to share. With such a low float, any positive news could translate into a sharp move in the stock price.🔥🔥🔥 ⚠️ Not investment advice — just my personal view.
1 · Reply
Vedran1
Vedran1 Sep. 7 at 4:19 AM
$RNAZ Link to the August Shareholder Meeting Playback: https://east.virtualshareholdermeeting.com/vsm/web?pvskey=RNAZ2025
0 · Reply
RNAZ089
RNAZ089 Sep. 6 at 1:18 PM
$RNAZ Based on the remarks at the shareholders' meeting and the interim evaluation results, it is expected to be a definite success. Were there any other topics discussed at the shareholders' meeting? But I wonder why there's so little interest in the market.?? ...It's too quiet. Do others have any opinions?
1 · Reply
Meksss
Meksss Sep. 6 at 10:01 AM
$GRI $IBRX $KAPA $REVB $RNAZ
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz Sep. 5 at 11:20 PM
$GRI $IBRX $KAPA $REVB $RNAZ not sure about others but KAPA has two catalysts this month. If both good I expect good things . Lung cancer this weekend and the September 18 for prostate cancer
1 · Reply
Latest News on RNAZ
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025, 8:00 AM EDT - 3 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025, 8:05 AM EDT - 4 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025, 5:07 PM EDT - 4 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 4 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025, 9:01 AM EDT - 4 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Apr 21, 2025, 4:37 PM EDT - 4 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 27, 2025, 4:37 PM EDT - 5 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 25, 2025, 6:24 PM EDT - 5 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 23, 2025, 11:11 PM EDT - 6 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Mar 13, 2025, 7:47 AM EDT - 6 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 25, 2025, 4:15 PM EST - 6 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 6, 2025, 8:00 AM EST - 7 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 8 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Jan 7, 2025, 8:00 AM EST - 8 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 18, 2024, 8:00 AM EST - 9 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 29, 2024, 4:25 PM EST - 10 months ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 27, 2024, 7:00 AM EST - 10 months ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Nov 5, 2024, 7:00 AM EST - 10 months ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 12, 2024, 4:05 PM EST - 1 year ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Jan 4, 2024, 8:05 AM EST - 1 year ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 12, 2023, 8:30 AM EST - 1 year ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 5, 2023, 9:00 AM EST - 1 year ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Dec 4, 2023, 4:10 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 1 year ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Nov 14, 2023, 4:30 PM EST - 1 year ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 2 years ago

TransCode Therapeutics Withdraws Public Offering

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 27, 2023, 8:00 AM EDT - 2 years ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 4:19 PM EDT - 2 years ago

TransCode Therapeutics Announces Public Offering of Common Stock

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 26, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Oct 16, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Sep 28, 2023, 4:02 PM EDT - 2 years ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Scrubinski
Scrubinski Sep. 8 at 2:06 PM
$RNAZ is it early September yet?
0 · Reply
mbr60
mbr60 Sep. 8 at 1:49 PM
$RNAZ i think tomorrow 🔥🔥🔥
1 · Reply
Hovius
Hovius Sep. 8 at 1:03 PM
$RNAZ this all sounds beautiful, except for one thing…
0 · Reply
RNAZ089
RNAZ089 Sep. 8 at 12:38 PM
$RNAZ $OCTO wtf.................1000%....wow
0 · Reply
RNAZ089
RNAZ089 Sep. 7 at 10:58 PM
$RNAZ So here's my take: They did the reverse split in May, then the big players stepped in and started scooping up shares. After the July 23 cohort approval, we saw another round of heavy accumulation. If real news drops, I think the move will make July 23 look tiny. Only 800k shares out there + super low market cap = this thing has TEN-BAGGER written all over it. ■■This trial is the company's very first clinical - apart from the preclinical stage■■ 🚀 🚀 🚀
1 · Reply
drstock07
drstock07 Sep. 7 at 6:55 PM
$RNAZ The company completed Phase 1 with 16 patients, and some are still ongoing in the study. All prior updates confirmed no dose-limiting toxicities (No DLTs), which is a major strength at this stage. In the latest shareholders’ meeting, management clearly stated they expect to announce specific results in early September. Companies usually don’t commit to a timeframe unless they have clear and encouraging data to share. With such a low float, any positive news could translate into a sharp move in the stock price.🔥🔥🔥 ⚠️ Not investment advice — just my personal view.
1 · Reply
Vedran1
Vedran1 Sep. 7 at 4:19 AM
$RNAZ Link to the August Shareholder Meeting Playback: https://east.virtualshareholdermeeting.com/vsm/web?pvskey=RNAZ2025
0 · Reply
RNAZ089
RNAZ089 Sep. 6 at 1:18 PM
$RNAZ Based on the remarks at the shareholders' meeting and the interim evaluation results, it is expected to be a definite success. Were there any other topics discussed at the shareholders' meeting? But I wonder why there's so little interest in the market.?? ...It's too quiet. Do others have any opinions?
1 · Reply
Meksss
Meksss Sep. 6 at 10:01 AM
$GRI $IBRX $KAPA $REVB $RNAZ
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz Sep. 5 at 11:20 PM
$GRI $IBRX $KAPA $REVB $RNAZ not sure about others but KAPA has two catalysts this month. If both good I expect good things . Lung cancer this weekend and the September 18 for prostate cancer
1 · Reply
makedatbread88
makedatbread88 Sep. 5 at 10:58 PM
September known data catalysts to watch closely $RNAZ $REVB $KAPA $GRI $IBRX At least one of these will run hard let's see!
0 · Reply
drstock07
drstock07 Sep. 5 at 2:15 PM
$RNAZ I agree with your points and share the same conviction. Wishing success for everyone, and hopefully we’ll hear positive news soon. 🙏🚀
0 · Reply
Hovius
Hovius Sep. 5 at 1:44 PM
$RNAZ Why is this going down? I haven’t bought any yet… 😝
1 · Reply
mbr60
mbr60 Sep. 5 at 1:30 PM
$RNAZ Cash runway: the company stated it has enough cash to fund operations through year-end. Clinical: year-to-date updates reported no dose-limiting toxicities and signs of activity (stable disease in some patients). Shorts: I’m watching the T+4 short data; a jump there could matter if news hits. **Not investment advice — just my opinion.** 😁
0 · Reply
RNAZ089
RNAZ089 Sep. 5 at 1:14 PM
$RNAZ Someone stacked a sell wall of 1,000 shares. Maybe an insider who knows something is already unloading slowly?
1 · Reply
RNAZ089
RNAZ089 Sep. 5 at 12:58 PM
$RNAZ Weak U.S. economic data could lead to rate cuts, which would be a positive for RNAZ since the company needs to borrow money." Still, positive clinical results are a must. With good news, the upside could be huge, but if the trial fails, we're basically doomed.
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 5 at 11:45 AM
$RNAZ MADE SOME CHANGES TO U FOR NEXT WEEK
1 · Reply
Hovius
Hovius Sep. 5 at 11:36 AM
$RNAZ if news comes out today or preferred way, late Sunday night (thanks for that one), everyone who bought this is done for.
0 · Reply
drstock07
drstock07 Sep. 5 at 11:18 AM
$RNAZ In my view, I believe the announcement will likely come either on Monday or Thursday. I expect the stock price to reach around $28 on the first announcement. With a more detailed follow-up announcement, I see the potential for substantial therapeutic results, which could drive the stock toward $40. Low-float stocks typically react strongly to meaningful positive news, making these projections realistic.
0 · Reply
RNAZ089
RNAZ089 Sep. 5 at 10:15 AM
$RNAZ However, if the shareholder meeting went well and the results were positive, a small-float stock like this should normally be moving up. The fact that it's just drifting sideways without any volume looks like a negative signal.
2 · Reply
RNAZ089
RNAZ089 Sep. 5 at 8:21 AM
$RNAZ Five out of fifteen people dropped out—could this be related to side effects of the drug???????
1 · Reply
rock_it_stocks
rock_it_stocks Sep. 5 at 6:50 AM
$RNAZ Crunch time! Which way will it go? ATL at $6.15.
0 · Reply